NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives $44.30 Consensus Price Target from Analysts

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) has been given a consensus recommendation of “Moderate Buy” by the ten brokerages that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $44.30.

A number of research analysts have recently commented on the company. Wells Fargo & Company assumed coverage on NewAmsterdam Pharma in a report on Monday, August 25th. They issued an “overweight” rating and a $45.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Wednesday, October 8th. HC Wainwright began coverage on shares of NewAmsterdam Pharma in a report on Monday, October 20th. They set a “buy” rating and a $52.00 price objective on the stock. Royal Bank Of Canada boosted their price objective on shares of NewAmsterdam Pharma from $39.00 to $44.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Finally, Citigroup increased their target price on shares of NewAmsterdam Pharma from $42.00 to $50.00 and gave the company a “buy” rating in a research report on Friday, October 17th.

NewAmsterdam Pharma Trading Up 0.9%

Shares of NAMS opened at $38.91 on Friday. The firm has a market capitalization of $4.41 billion, a price-to-earnings ratio of -18.98 and a beta of 0.05. The firm’s fifty day simple moving average is $33.26 and its 200-day simple moving average is $25.48. NewAmsterdam Pharma has a twelve month low of $14.06 and a twelve month high of $41.47.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its earnings results on Wednesday, November 5th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.03). The business had revenue of $0.35 million during the quarter, compared to analysts’ expectations of $4.54 million. NewAmsterdam Pharma had a negative net margin of 627.59% and a negative return on equity of 28.30%. On average, analysts predict that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.

Insider Buying and Selling at NewAmsterdam Pharma

In related news, CAO Louise Frederika Kooij sold 150,000 shares of the company’s stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $25.83, for a total value of $3,874,500.00. Following the completion of the sale, the chief accounting officer directly owned 15,000 shares of the company’s stock, valued at $387,450. This represents a 90.91% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Johannes Jacob Piete Kastelein sold 50,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 21st. The stock was sold at an average price of $24.29, for a total value of $1,214,500.00. Following the transaction, the insider owned 119,302 shares in the company, valued at $2,897,845.58. This represents a 29.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 226,342 shares of company stock worth $5,748,019 over the last 90 days. Corporate insiders own 20.84% of the company’s stock.

Institutional Investors Weigh In On NewAmsterdam Pharma

Several large investors have recently modified their holdings of NAMS. Quarry LP purchased a new stake in NewAmsterdam Pharma in the 1st quarter valued at $25,000. Mather Group LLC. acquired a new position in NewAmsterdam Pharma in the 3rd quarter valued at $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new position in shares of NewAmsterdam Pharma during the third quarter worth about $30,000. Wolverine Asset Management LLC purchased a new position in shares of NewAmsterdam Pharma during the 3rd quarter worth approximately $69,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in NewAmsterdam Pharma by 18.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,337 shares of the company’s stock worth $79,000 after acquiring an additional 662 shares in the last quarter. 89.89% of the stock is owned by institutional investors and hedge funds.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.